Products for Research Use Only

Revaprazan

CAT: 0804-HY-121851Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-121851Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer[1][2].
CAS Number
199463-33-7
Product Name Alternative
SB 641257
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Akt; Bacterial; COX; ERK; NF-κB; Proton Pump
Type
Reference compound
Related Pathways
Anti-infection; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/revaprazan.html
Solubility
10 mM in DMSO
Smiles
CC1=C(C)C(N2C(C)C3=C(C=CC=C3)CC2)=NC(NC4=CC=C(F)C=C4)=N1
Molecular Formula
C22H23FN4
Molecular Weight
362.44
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
[1]Lee JS, et al. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J Clin Biochem Nutr. 2012 Sep;51 (2) :77-83. |[2]Kim HK, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010 Oct;25 (10) :1618-25.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-2
Citation 01
Pharmaceuticals (Basel) . 2022 Sep 25;15 (10) :1186.|BMC Microbiol. 2025 Nov 5;25 (1) :715.